Bone marrow transplants are offering renewed hope to patients battling complex blood cancers and inherited blood disorders, with Apollo Hospitals Navi Mumbai completing 100 procedures since launching its specialised programme in February 2019. The milestone reflects the hospital’s growing expertise in advanced transplant medicine and its expanding ability to treat both adult and paediatric patients requiring potentially curative therapies.
Apollo’s Growing Role in Advanced Healthcare
Apollo Hospitals has been a major force in India’s modern healthcare landscape since Dr Prathap C. Reddy established its first hospital in Chennai in 1983. Over the decades, the group has expanded into an integrated healthcare network spanning hospitals, pharmacies, clinics, diagnostic centres and telemedicine services, while investing heavily in advanced medical technology, research and specialised treatment.
From Three Beds to a Six-Bed Programme
The Bone Marrow Transplant programme began just months before the COVID-19 pandemic, presenting an immediate challenge to its development. Despite the unprecedented disruption, the programme continued to evolve from a three-bed BMT unit into a dedicated six-bed facility.
The programme is led by Dr Punit Jain, Lead Consultant – Haematology, Haemato-Oncology & Bone Marrow Transplantation & CAR T-Cell Therapy, along with Dr Vipin Khandelwal, Senior Consultant – Paediatric Haemato-Oncology & Bone Marrow Transplantation.
Its multidisciplinary infrastructure includes specialised isolation facilities, a full-fledged blood bank, intensive-care support, infectious-disease expertise, gastroenterology and dermatology teams, and dedicated haemato-oncology nursing staff.
Expanding Access Through Advanced Transplantation
The centre treats a wide spectrum of conditions, including acute and chronic leukaemias, multiple myeloma, lymphomas, aplastic anaemia, myelodysplastic syndromes, thalassaemia, sickle cell disease and primary immunodeficiency disorders.
Dr Jain emphasised that early referral is increasingly critical. Advances in haploidentical transplantation mean that lack of a fully matched donor is no longer necessarily an insurmountable barrier. Early assessment can therefore widen treatment possibilities and influence outcomes.
Hope for Children and Complex Cases
Paediatric transplantation remains another important component. Dr Khandelwal highlighted the potential role of timely transplantation for children with thalassaemia, sickle cell disease, aplastic anaemia and selected immunodeficiency disorders.
The centre has also performed four CAR T-cell therapies for patients with relapsed or refractory B-cell lymphomas and leukaemias, extending its advanced treatment capabilities beyond conventional transplantation.
A Milestone Built on Multidisciplinary Care
Despite treating highly complex patients, the programme has reported survival outcomes exceeding 70%, which the hospital says are comparable with internationally published standards. Its growth demonstrates how specialised infrastructure, experienced clinicians and coordinated multidisciplinary care can strengthen outcomes in transplant medicine.
Early Intervention Can Change the Treatment Journey
The 100-transplant milestone is more than a numerical achievement; it highlights the importance of specialised expertise and timely access to advanced therapies. As blood cancers and inherited disorders continue to challenge patients and families, greater awareness among physicians and communities can encourage earlier evaluation. For many patients, the difference between waiting and timely referral may ultimately determine whether transplantation becomes an option for a potentially curative treatment journey.
